TargetMol

Mcl1-IN-26

Product Code:
 
TAR-T24436
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T24436-5mg5mg£850.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Mcl1-IN-26 is an effective and selective myeloid cell leukemia 1 inhibitor.
CAS:
2056238-04-9
Formula:
C45H52ClN5O6S
Molecular Weight:
826.45
Purity:
0.98
SMILES:
[H][C@@]12CCc3ccccc3N(CC(=O)N[C@H](Cc3ccc(Cl)c(CCc4ccccc4)c3)CC(=O)N(C)CCCN[C@@H](Cc3ccc(cc3)S(C)(=O)=O)CC(=O)N1)C2=O

References

1. Alyafee YA, Alaamery M, Bawazeer S, Almutairi MS, Alghamdi B, Alomran N, Sheereen A, Daghestani M, Massadeh S. Preparation of anastrozole loaded PEG-PLA nanoparticles: evaluation of apoptotic response of breast cancer cell lines. Int J Nanomedicine. 2017 Dec 28;13:199-208. doi: 10.2147/IJN.S151139. eCollection 2018. PubMed PMID: 29343958; PubMed Central PMCID: PMC5749378. 2. Ponder KG, Matulis SM, Hitosugi S, Gupta VA, Sharp C, Burrows F, Nooka AK, Kaufman JL, Lonial S, Boise LH. Dual inhibition of Mcl-1 by the combination of carfilzomib and TG02 in multiple myeloma. Cancer Biol Ther. 2016 Jul 2;17(7):769-77. doi: 10.1080/15384047.2016.1192086. PubMed PMID: 27246906; PubMed Central PMCID: PMC4970534. 3. Pallis M, Burrows F, Ryan J, Grundy M, Seedhouse C, Abdul-Aziz A, Montero J, Letai A, Russell N. Complementary dynamic BH3 profiles predict co-operativity between the multi-kinase inhibitor TG02 and the BH3 mimetic ABT-199 in acute myeloid leukaemia cells. Oncotarget. 2017 Mar 7;8(10):16220-16232. doi: 10.18632/oncotarget.8742. PubMed PMID: 27092880; PubMed Central PMCID: PMC5369958. 4. Bashari MH, Fan F, Vallet S, Sattler M, Arn M, Luckner-Minden C, Schulze-Bergkamen H, Z?rnig I, Marme F, Schneeweiss A, Cardone MH, Opferman JT, J?ger D, Podar K. Mcl-1 confers protection of Her2-positive breast cancer cells to hypoxia: therapeutic implications. Breast Cancer Res. 2016 Feb 26;18(1):26. doi: 10.1186/s13058-016-0686-4. PubMed PMID: 26921175; PubMed Central PMCID: PMC4769490.